1. Home
  2. CMND
  3. CMND News

Latest Clearmind Medicine Inc. (CMND) News on November 6, 2025

Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
CMND

GlobeNewswire

6 days ago

Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy

Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
CMND

GlobeNewswire

7 days ago

Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
CMND

GlobeNewswire

16 days ago

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

CMND

MT Newswires

17 days ago

Clearmind Says US Patent Application Published Targeting Binge Behavior Disorders

Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder
CMND

GlobeNewswire

4 months ago

Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder

Clearmind Medicine expands global clinical trial targeting AUD market
CMND

TipRanks

4 months ago

Clearmind Medicine expands global clinical trial targeting AUD market

Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
CMND

TipRanks

4 months ago

Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial

CMND

MT Newswires

4 months ago

Clearmind Adds New Site to Trial for Experimental Alcohol Use Disorder Drug

Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market
CMND

GlobeNewswire

4 months ago

Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market

Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment
CMND

GlobeNewswire

4 months ago

Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment

Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
CMND

GlobeNewswire

4 months ago

Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics

Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
CMND

GlobeNewswire

4 months ago

Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder

Trump Trade: President said to weigh possible U.S. strike against Iran
CMND

TipRanks

5 months ago

Trump Trade: President said to weigh possible U.S. strike against Iran

Psychedelic advocates hopeful Trump administration will support space, STAT says
CMND

TipRanks

5 months ago

Psychedelic advocates hopeful Trump administration will support space, STAT says

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics
CMND

GlobeNewswire

5 months ago

Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics

Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment
CMND

GlobeNewswire

5 months ago

Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
CMND

GlobeNewswire

6 months ago

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
CMND

GlobeNewswire

6 months ago

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

Psychedelic: Clearmind completes clinical site initiations for AUD trial
CMND

TipRanks

6 months ago

Psychedelic: Clearmind completes clinical site initiations for AUD trial

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
CMND

GlobeNewswire

6 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
CMND

GlobeNewswire

6 months ago

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites
CMND

GlobeNewswire

6 months ago

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
CMND

GlobeNewswire

7 months ago

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior
CMND

GlobeNewswire

7 months ago

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior

Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
CMND

GlobeNewswire

7 months ago

Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism

Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
CMND

TipRanks

7 months ago

Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
CMND

GlobeNewswire

7 months ago

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
CMND

GlobeNewswire

7 months ago

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
CMND

GlobeNewswire

7 months ago

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment

Psychedelic: Exclusive talk with biotech company Clearmind Medicine
CMND

TipRanks

7 months ago

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

Psychedelic: atai Life Sciences, NRx report quarterly results
CMND

TipRanks

7 months ago

Psychedelic: atai Life Sciences, NRx report quarterly results

Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
CMND

GlobeNewswire

8 months ago

Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
CMND

GlobeNewswire

8 months ago

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients
CMND

GlobeNewswire

8 months ago

Clearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
CMND

TipRanks

8 months ago

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
CMND

GlobeNewswire

8 months ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
CMND

GlobeNewswire

8 months ago

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Psychedelic: GH Research, Compass Pathways report earnings results
CMND

TipRanks

8 months ago

Psychedelic: GH Research, Compass Pathways report earnings results

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
CMND

GlobeNewswire

9 months ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
CMND

GlobeNewswire

9 months ago

Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico

Clearmind Medicine Announces Shareholders Meeting Results
CMND

GlobeNewswire

10 months ago

Clearmind Medicine Announces Shareholders Meeting Results

Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
CMND

GlobeNewswire

10 months ago

Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
CMND

GlobeNewswire

10 months ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
CMND

GlobeNewswire

10 months ago

Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office

Clearmind Medicine to move forward with MEAI-based alcohol substitute
CMND

TipRanks

10 months ago

Clearmind Medicine to move forward with MEAI-based alcohol substitute

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
CMND

GlobeNewswire

10 months ago

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
CMND

GlobeNewswire

10 months ago

Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial

Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
CMND

GlobeNewswire

a year ago

Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
CMND

GlobeNewswire

a year ago

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
CMND

GlobeNewswire

a year ago

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
CMND

GlobeNewswire

a year ago

Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
CMND

GlobeNewswire

a year ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
CMND

GlobeNewswire

a year ago

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
CMND

GlobeNewswire

a year ago

Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment

CMND

Market Exclusive

a year ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
CMND

GlobeNewswire

a year ago

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
CMND

GlobeNewswire

a year ago

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders

SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
CMND

GlobeNewswire

a year ago

SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
CMND

GlobeNewswire

a year ago

Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug

Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
CMND

GlobeNewswire

a year ago

Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
CMND

GlobeNewswire

a year ago

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product

Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
CMND

GlobeNewswire

a year ago

Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
CMND

GlobeNewswire

a year ago

SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
CMND

GlobeNewswire

a year ago

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
CMND

GlobeNewswire

a year ago

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference

Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
CMND

GlobeNewswire

a year ago

Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment

Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
CMND

GlobeNewswire

a year ago

Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment

Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
CMND

GlobeNewswire

a year ago

Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
CMND

GlobeNewswire

a year ago

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
CMND

GlobeNewswire

a year ago

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

Clearmind Applies to Cease Being a Reporting Issuer in Canada
CMND

GlobeNewswire

2 years ago

Clearmind Applies to Cease Being a Reporting Issuer in Canada

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
CMND

GlobeNewswire

2 years ago

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
CMND

GlobeNewswire

2 years ago

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Clearmind Medicine CEO Issues Letter to Shareholders
CMND

GlobeNewswire

2 years ago

Clearmind Medicine CEO Issues Letter to Shareholders

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
CMND

GlobeNewswire

2 years ago

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
CMND

GlobeNewswire

2 years ago

Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
CMND

GlobeNewswire

2 years ago

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
CMND

GlobeNewswire

2 years ago

Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
CMND

GlobeNewswire

2 years ago

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
CMND

GlobeNewswire

2 years ago

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

Clearmind Medicine receives Patent Approval in China for treatment of binge behaviours
CMND

News Direct

2 years ago

Clearmind Medicine receives Patent Approval in China for treatment of binge behaviours

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
CMND

GlobeNewswire

2 years ago

Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
CMND

GlobeNewswire

2 years ago

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
CMND

GlobeNewswire

2 years ago

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

CMND

Market Exclusive

2 years ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

CMND

GlobeNewswire

2 years ago

Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
CMND

GlobeNewswire

2 years ago

Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center

University Expands Emergency Communication Conversion with Knightscope
CMND

Business Wire

2 years ago

University Expands Emergency Communication Conversion with Knightscope

Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
CMND

ACCESSWIRE

2 years ago

Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CMND

Newsfile

2 years ago

Envoy Medical, Inc. to Present at The Microcap Conference

Fortune 500 Client Renews Knightscope Agreement for 3rd Year
CMND

Business Wire

2 years ago

Fortune 500 Client Renews Knightscope Agreement for 3rd Year

ISG to Publish Reports on Google Cloud Ecosystem
CMND

Business Wire

2 years ago

ISG to Publish Reports on Google Cloud Ecosystem

SINTX TECHNOLOGIES SHARES SELECT PRELIMINARY Q4 2023 AND FULL YEAR 2023 REVENUE UPDATE
CMND

GlobeNewswire

2 years ago

SINTX TECHNOLOGIES SHARES SELECT PRELIMINARY Q4 2023 AND FULL YEAR 2023 REVENUE UPDATE

PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application
CMND

GlobeNewswire

2 years ago

PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application

Air T, Inc. Announces Dividend Dates for Air T Funding Alpha Income Preferred Securities (AIRTP)
CMND

ACCESSWIRE

2 years ago

Air T, Inc. Announces Dividend Dates for Air T Funding Alpha Income Preferred Securities (AIRTP)

MCRA Provides Anzu Special Acquisition Corp I with Strategic Diligence Support Leading to Envoy Medical Merger (NASDAQ: COCH)
CMND

PR Newswire

2 years ago

MCRA Provides Anzu Special Acquisition Corp I with Strategic Diligence Support Leading to Envoy Medical Merger (NASDAQ: COCH)

EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market’s Continued Listing Requirements After receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency
CMND

GlobeNewswire

2 years ago

EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market’s Continued Listing Requirements After receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)
CMND

ACCESSWIRE

2 years ago

Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)

Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
CMND

GlobeNewswire

2 years ago

Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement

ReWalk Robotics Expands Direct Sales Coverage to Canada
CMND

GlobeNewswire

2 years ago

ReWalk Robotics Expands Direct Sales Coverage to Canada

Share on Social Networks: